The UK and US have announced a landmark trade agreement that will ensure zero levies on UK medicine shipments being sold in the US market.
The Terms of the Accord
Under the terms of the agreement, the UK has pledged to raise spending on medicines through the public health system. This commitment ensures that tariffs on these key products will remain at nothing for a duration of the next three years.
This development follows recent threats to significantly raise duties on branded drug imports, with figures discussed reaching 100%.
"This deal with the Britain reinforces the international landscape for innovative medicines and establishes much-needed balance to U.S.–U.K. pharmaceutical trade," a statement noted.
Commercial Importance
Drugs represent one of the Britain's most significant export categories to the America, which is by far the primary buyer for leading UK drugmakers.
Export figures show that in the year to the end of September, the UK exported pharmaceutical products totaling over eleven billion pounds to the US. This amount represented nearly one-fifth of all goods exports in that period.
"This deal protects employment, boosts investment and paves the way for the UK to emerge as a international leader for medical research," a government official stated.
Key UK Commitments
The agreement entails several specific changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it deems new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to double total health service expenditure on medicines from 0.3% of GDP to 0.6 percent over the coming ten years.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be capped at 15%. Previously, repayments topped twenty percent.
Broader Context
The deal takes place against a protracted dispute between the pharmaceutical industry and the British authorities over spending levels and approval rates.
The disagreement were heightened by arguments that US customers were charged a premium for the identical medicines than patients in the UK and Europe.
In recent months, several large drug company projects in the UK have been halted or cancelled, while multi-billion-dollar funding commitments have been announced toward US facilities.
A senior figure stated that the NHS had to invest a greater share on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the previous ten-year period.
